Literature DB >> 17868996

Copolymer-1 (Cop-1) improves neurological recovery after middle cerebral artery occlusion in rats.

Antonio Ibarra1, Héctor Avendaño, Yolanda Cruz.   

Abstract

The damage in ischemic stroke is caused by two events: (i) the ischemic phenomenon by itself; (ii) the self-destructive mechanisms developed as a consequence of ischemia. The inflammatory response is one of these destructive phenomena that accompanies and exacerbates the developing injury. Since it has been suggested that immune cells participate in neuroprotective and restorative processes, modulation rather than elimination of this inflammatory response could be a strategy to improve the neurological outcome. The immune modulator copolymer-1 (Cop-1), a synthetic basic random copolymer of amino acids, is a potent inducer of Th2 regulatory cells which, aside from exerting modulatory actions, is capable of releasing neurotrophic factors. There is evidence that Cop-1-specific T cells exert neuroprotective and even restorative effects in diverse neurodegenerative diseases. In order to test the ability of Cop-1 to prevent ischemic injury in a model of transient middle cerebral artery (MCA) occlusion, two groups of rats were treated either with Cop-1 or with saline solution (SS). Seven days after occlusion, Cop-1 treated rats presented a significant improvement in neurological function compared to SS-treated animals (1.2+/-0.4 and 2.8+/-0.5 mean+/-S.D., respectively; p=0.008). Histological findings showed that the percentage of infarct volume was smaller in Cop-1 treated rats (4.8+/-1.5), in comparison with those receiving SS (32.2+/-8.6; p=0.004). Cop-1 constitutes a promising therapy for stroke; thereby, the enforcement of further experimental investigation is encouraged in order to be able to formulate the best strategy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17868996     DOI: 10.1016/j.neulet.2007.08.038

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  14 in total

1.  Brain dendritic cells in ischemic stroke: time course, activation state, and origin.

Authors:  Jennifer C Felger; Takato Abe; Ulrike W Kaunzner; Andres Gottfried-Blackmore; Judit Gal-Toth; Bruce S McEwen; Costantino Iadecola; Karen Bulloch
Journal:  Brain Behav Immun       Date:  2009-11-13       Impact factor: 7.217

Review 2.  Lymphocytes and ischemia-reperfusion injury.

Authors:  Douglas Linfert; Tayseer Chowdhry; Hamid Rabb
Journal:  Transplant Rev (Orlando)       Date:  2009-01       Impact factor: 3.943

Review 3.  Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system?

Authors:  Babak Jalilian; Halldór Bjarki Einarsson; Thomas Vorup-Jensen
Journal:  Int J Mol Sci       Date:  2012-11-09       Impact factor: 5.923

4.  Copolymer-1 promotes neurogenesis and improves functional recovery after acute ischemic stroke in rats.

Authors:  Yolanda Cruz; Jonathan Lorea; Humberto Mestre; Jennifer Hyuna Kim-Lee; Judith Herrera; Raúl Mellado; Vanesa Gálvez; Leopoldo Cuellar; Carolina Musri; Antonio Ibarra
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

Review 5.  Heterogeneity of B Cell Functions in Stroke-Related Risk, Prevention, Injury, and Repair.

Authors:  Uma Maheswari Selvaraj; Katherine Poinsatte; Vanessa Torres; Sterling B Ortega; Ann M Stowe
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

6.  Immunization with neural derived peptides plus scar removal induces a permissive microenvironment, and improves locomotor recovery after chronic spinal cord injury.

Authors:  Roxana Rodríguez-Barrera; Adrián Flores-Romero; Ana María Fernández-Presas; Elisa García-Vences; Raúl Silva-García; Mina Konigsberg; Liliana Blancas-Espinoza; Vinnitsa Buzoianu-Anguiano; Karla Soria-Zavala; Paola Suárez-Meade; Antonio Ibarra
Journal:  BMC Neurosci       Date:  2017-01-05       Impact factor: 3.288

7.  Potentially Common Therapeutic Targets for Multiple Sclerosis and Ischemic Stroke.

Authors:  Roberto Paternò; Jean-Marc Chillon
Journal:  Front Physiol       Date:  2018-07-13       Impact factor: 4.566

8.  Glatiramer acetate does not protect from acute ischemic stroke in mice.

Authors:  Peter Kraft; Kerstin Göbel; Sven G Meuth; Christoph Kleinschnitz
Journal:  Exp Transl Stroke Med       Date:  2014-02-27

9.  Immunization with Cop-1 promotes neuroprotection and neurogenesis after ischemic stroke.

Authors:  Yolanda Cruz; Paola Suárez-Meade; Antonio Ibarra
Journal:  Neural Regen Res       Date:  2015-11       Impact factor: 5.135

Review 10.  Immunotherapy of experimental and human stroke with agents approved for multiple sclerosis: a systematic review.

Authors:  Mirjam Dreikorn; Zeljko Milacic; Vladimir Pavlovic; Sven G Meuth; Christoph Kleinschnitz; Peter Kraft
Journal:  Ther Adv Neurol Disord       Date:  2018-04-20       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.